Cellectis S.A.CLLSEarnings & Financial Report
Nasdaq · Health Care
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| AstraZeneca Holdings B.V. | 22.40% | 16.0M | flat | 2023-11-16 |
| NOS. OF ABOVE PERSONS | 6.30% | 4.5M | ▲ +3.24pp | 2024-02-14 |
| Bpifrance Participations S.A. | 5.90% | 5.9M | ▼ -2.30pp | 2024-05-21 |
| s. PFIZER INC. | 3.89% | 2.8M | — | 2024-02-14 |